Aside from disease-modifying therapies, patients can make many kinds of lifestyle modifications, as the panelists list here, that can improve the functioning of their central nervous system.
The glucose-lowering medication lixisenatide was found not to increase or decrease cardiovascular (CV) events compare with placebo in patients afflicted with type 2 diabetes and acute coronary syndrome.
Talking to a new patient about MS can be a complicated and sensitive matter. Hear the panelists offer their suggestions for having discussions with patients and families, and what to do in the case of treatment failure.
There could be a new first-line treatment for hypertension in patients needing diuretic therapy, according to research presented at the European Society of Cardiology (ESC) Congress conference in London, UK.
In heart failure patients with diabetes and/or chronic kidney disease, a new, non-steroidal mineralocorticoid receptor antagonist called finerenone was no more effective than the currently approved MRA eplerenone in reducing the heart failure biomarker N-terminal pro-B-type natriuretic peptide. But it had other benefits.
New research on the link between diabetes and pancreatitis has shown a strong association between the severity of pancreatic dysfunction and subsequent risk of developing type 2 diabetes mellitus.
Women seek medical care more frequently than men after treatment for asthma in the emergency department, according to findings published in the Annals of Allergy, Asthma & Immunology.
Researchers in Scotland found that in a trial involving more tha n 7,000 patients, the rates of adverse cardiac and other negative outcomes were about the same whether these patients took NSAIDs or COX-2 inhibitors.
Representing two of the major conferences in the cardiac world the American College of Cardiology and the European Society of Cardiology have found ways to work together to help patients on both sides of the Atlantic.